We are live on ! Find out more
DTC

Deep Track Capital Portfolio holdings

AUM $6.12B
1-Year Est. Return 144%
This Fund
S&P 500
This Quarter Est. Return
+8.63%
1 Year Est. Return
+144%
3 Year Est. Return
+348.41%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$3.12B
AUM Growth
+$30M
Cap. Flow
-$55.4M
Cap. Flow %
-1.78%
Top 10 Hldgs %
52.44%
Holding
76
New
7
Increased
18
Reduced
21
Closed
10

Top Buys

Rank Stock Value
1
INSM icon
Insmed
INSM
+$114M
2
JBIO
Jade Biosciences
JBIO
+$85.4M
3
AXSM icon
Axsome Therapeutics
AXSM
+$84.9M
4
PCVX icon
Vaxcyte
PCVX
+$45.9M
5
APLS
Apellis Pharmaceuticals
APLS
+$37M

Top Sells

Rank Stock Value
1
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$264M
2
BBIO icon
BridgeBio Pharma
BBIO
+$69.1M
3
GH icon
Guardant Health
GH
+$53.3M
4
AMGN icon
Amgen
AMGN
+$35.2M
5
EWTX icon
Edgewise Therapeutics
EWTX
+$30.8M

Sector Composition

Rank Sector Weight
1 Healthcare 99.75%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BBIO icon
26
BridgeBio Pharma
BBIO
$16.4B
$38.9M 1.25%
900,000
-1,900,000
-68% -$69.1M
AUTL
27
Autolus Therapeutics
AUTL
$389M
$38.4M 1.23%
16,852,147
-997,335
-6% -$1.65M
MTSR
28
DELISTED
Metsera Inc
MTSR
$31.1M 1%
1,094,408
– –
TERN
29
DELISTED
Terns Pharmaceuticals
TERN
$28M 0.9%
7,495,000
+1,918,442
+34% +$5.99M
TECX
30
Tectonic Therapeutic
TECX
$536M
$27.9M 0.89%
1,401,938
– –
ABVX
31
Abivax
ABVX
$10.4B
$26.6M 0.85%
3,480,144
-99,065
-3% -$646K
JBIO
32
Jade Biosciences
JBIO
$1.18B
$25.1M 0.8%
+2,509,301
New +$85.4M
MBX
33
MBX Biosciences
MBX
$3.04B
$25M 0.8%
2,188,592
-830,343
-28% -$8.46M
CMPS
34
Compass Pathways
CMPS
$1.47B
$24.7M 0.79%
8,831,007
-28,641
-0.3% -$108K
GHRS icon
35
GH Research
GHRS
$1.92B
$24.4M 0.78%
2,000,000
– –
BCAX
36
Bicara Therapeutics
BCAX
$1.7B
$22.5M 0.72%
2,426,657
+426,657
+21% +$5.08M
ORKA
37
Oruka Therapeutics
ORKA
$5.31B
$21.5M 0.69%
1,918,798
+474,089
+33% +$4.94M
ENGN icon
38
enGene Therapeutics
ENGN
$120M
$16.6M 0.53%
4,557,575
– –
DFTX
39
Definium Therapeutics
DFTX
$5.6B
$16.2M 0.52%
2,500,000
– –
UPB
40
Upstream Bio Inc
UPB
$349M
$15.8M 0.51%
1,442,767
-856,800
-37% -$7.91M
OLMA icon
41
Olema Pharmaceuticals
OLMA
$977M
$14.7M 0.47%
3,442,833
– –
MRUS
42
DELISTED
Merus
MRUS
$14.5M 0.46%
+275,000
New +$12.9M
HELP
43
Cybin Inc
HELP
$490M
$12.8M 0.41%
1,529,987
– –
CDTX
44
DELISTED
Cidara Therapeutics
CDTX
$12.2M 0.39%
+250,000
New +$6.01M
BCYC
45
Bicycle Therapeutics
BCYC
$269M
$8.36M 0.27%
1,203,244
+436,228
+57% +$3.47M
SRPT icon
46
PUT
Sarepta Therapeutics
SRPT
$1.64B
$7.7M 0.25%
+450,000
New +$19.2M
CBIO
47
Crescent Biopharma
CBIO
$546M
$7.32M 0.23%
+453,686
New +$9.6M
CNTA
48
DELISTED
Centessa Pharmaceuticals
CNTA
$6.57M 0.21%
+500,000
New +$6.33M
NVAX icon
49
Novavax
NVAX
$1.21B
$6.29M 0.2%
998,542
-519,640
-34% -$3.44M
IVVD icon
50
Invivyd
IVVD
$160M
$6.14M 0.2%
8,585,980
-1,136,274
-12% -$806K
1
2
3 4

Similar funds

AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.13B AUM 23.41% 1-Year Est. Return
ACM
AKRE Capital Management Middleburg, Virginia $6.13B AUM 15.27% 1-Year Est. Return
CIS
Capital International Sarl Los Angeles, California $6.11B AUM 32.29% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
JWBC
John W. Bristol & Co New York $6.08B AUM 16.51% 1-Year Est. Return
EMPI
Elo Mutual Pension Insurance Espoo, Finland $6.06B AUM 24.33% 1-Year Est. Return
HPG
Harvest Portfolios Group Oakville, Ontario, Canada $6.06B AUM 16.63% 1-Year Est. Return
B
Barings Charlotte, North Carolina $6.19B AUM 16.5% 1-Year Est. Return

Deep Track Capital's Q2 2025 Portfolio in Review

As of Q2 2025, Deep Track Capital held 76 positions worth $3.12B, up 0.97% from $3.09B the previous quarter. Its ten largest holdings account for 52% of the portfolio.

Deep Track Capital's Q2 2025 filing shows 7 new, 18 increased, 21 reduced and 10 closed positions. Its largest new stake was Jade Biosciences: 2,509,301 shares worth $25.1M. The largest sale was Intra-Cellular Therapies Inc., an estimated $264M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier.

  • Deep Track Capital's largest Q2 2025 buy was Jade Biosciences: 2,509,301 shares worth $25.1M.
  • Deep Track Capital added most to Insmed in Q2 2025, an estimated $114M increase.
  • Deep Track Capital's biggest Q2 2025 reduction was BridgeBio Pharma, cutting an estimated $69.1M.
  • Deep Track Capital fully exited Intra-Cellular Therapies Inc. in Q2 2025, selling an estimated $264M.
  • Deep Track Capital's ten largest holdings make up 52% of its $3.12B portfolio in Q2 2025.
  • Deep Track Capital opened 7 new positions and closed 10 in Q2 2025.
  • Deep Track Capital's portfolio value rose 0.97% quarter-over-quarter to $3.12B.

Based on Deep Track Capital's 13F filing for Q2 2025, filed 14 Aug 2025.